Hospital Virgen Del Camino
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Hospital Virgen Del Camino, the main focus is on cardiovascular disease research, with studies looking at atherosclerotic cardiovascular disease, heart failure, elevated lipoprotein(a), and broader vascular risk. These trials are designed to test new treatments that may lower the chance of serious heart and circulation-related events, while also improving symptoms and long-term outcomes.
- Studies in atherosclerotic cardiovascular disease and elevated Lp(a) are evaluating whether new therapies can better reduce major cardiovascular events.
- Research in heart failure includes approaches aimed at lowering hospital visits and improving daily functioning for people with reduced or preserved heart function.
- Several trials are examining treatments for people with cardiovascular disease at high risk, with the goal of preventing heart attack, stroke, and related complications.
Overall, this therapeutic area at the site reflects a strong emphasis on finding more effective ways to prevent serious cardiac and vascular events and to support people living with chronic heart conditions.
Nutritional and Metabolic Diseases
The Internal Medicine research program also includes studies in nutritional and metabolic diseases, especially obesity, type 2 diabetes mellitus, hypercholesterolemia, and chronic weight management. These trials are exploring new therapies that may help with weight reduction, metabolic control, and the prevention of complications linked to excess body weight and diabetes.
- Trials in obesity and overweight are testing whether new treatments can support meaningful and sustained weight loss.
- Research in type 2 diabetes mellitus is assessing whether treatments can also lower cardiovascular risk in people with diabetes.
- Studies involving hypercholesterolemia and related lipid disorders are focused on improving cholesterol control and reducing future disease risk.
These investigations show a clear interest in therapies that address both metabolic health and the long-term prevention of cardiovascular complications, reflecting an integrated approach to chronic disease care at the site.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1AstraZeneca AB2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Virgen Del Camino
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization | Novo Nordisk A/S | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2022-04-08 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.